Since the introduction of interferon beta-1b in 1993, the number of disease-modifying therapies for multiple sclerosis (MS) has grown at a remarkable pace. Currently there are 10 treatments approved by the US Food and Drug Administration, each with varying effects on important clinical and radiographic markers of disease activity.
↧
Disease Activity Free Status A New End Point for a New Era in Multiple Sclerosis Clinical Research?
↧